Getein Biotech hs-cTnI Successfully Achieves IFCC Certification     Recently, Getein Biotech chemiluminescence platform hs-cTnI received certification from the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), ensuring that its test results meet international standards of standardization and harmonization. This marks global recognition of the accuracy and compliance of Getein hs-cTnI testing technology. With standardized, compact, and efficient products, it helps medical institutions at all levels reduce the workload and improve the efficiency of cardiovascular disease testing.     Cardiac troponin (cTn) is currently recognized as the most specific cardiac biomarker and is found mainly in cardiomyocytes. When these cells are injured, cTn is rapidly released into the bloodstream. Because injury to other tissues or muscles rarely causes cTn elevation, cTn test results directly reflect cardiac injury and are among the most important biomarkers for diagnosing acute myocardial infarction (AMI). With the emergence of high-sensitivity cardiac troponin (hs-cTn) assays, detection sensitivity has improved substantially, enabling the identification of trace cardiac injuries that were previously difficult to detect. This allows earlier warning of cardiovascular disease risk and provides valuable time for early clinical intervention. IFCC Standardization Certification IFCC: The International Federation of Clinical Chemistry and Laboratory Medicine, founded in 1952, is one of the most influential international organizations in the fields of clinical chemistry and laboratory medicine. IFCC currently has members from 119 countries and regions. By collaborating with other international organizations to develop global standards, it continuously improves the accuracy, reliability, and comparability of laboratory testing. IFCC C-CB: The IFCC Committee on Cardiac Biomarkers is one of IFCC's core professional committees. It focuses on the standardization, clinical application, and quality control of cardiac biomarkers. Its guidelines have become a core reference for laboratories and clinicians in managing cardiac biomarkers, and continue to lead technological innovation and standardized development in this field. Getein Biotech chemiluminescence platform hs-cTnI has obtained NMPA certification and CE marking in 2022. Its successful inclusion in the IFCC Performance Reference Table further demonstrates that its excellent performance in analytical sensitivity and precision has reached internationally advanced levels.  Getein Biotech hs-cTnI is one of its core products built on a self-developed magnetic-particle chemiluminescence technology platform. Leveraging high-affinity antibody pairs and an optimized signal amplification system, it benchmarks against international leading standards in key metrics such as limit of detection (LoD) and precision (%CV). It delivers excellent clinical performance and rapid turnaround...

Getein at India Health 2026 - Innovative Diagnostics for a Brilliant Future Stand Stories: First-Day Buzz 〈New Delhi, August 21 2026〉— India Health 2026 is now underway at Bharat Mandapam, bringing together healthcare professionals, distributors, and industry partners from across India and surrounding markets. Since opening, Getein’s showcase at Hall 6, Booth C12 has drawn a steady stream of visitors eager to explore practical solutions for evolving diagnostic needs.     Presented by the organizers of WHX Dubai, formerly Arab Health, the three-day event serves as an important platform for healthcare innovation and regional collaboration. Through conversations on laboratory efficiency, decentralized testing, and market-specific applications, the Getein team is gaining valuable insights while building stronger connections with partners across the region. Spotlight on Solutions The products featured by Getein at this year's exhibition span chemiluminescence, point-of-care testing, and veterinary biochemistry. MAGICL 6000i streamlines laboratory workflows with a fully automated testing system and intelligent consumables and reagent management modules; the handheld Getein 1150 supports up to eight hours of battery-powered operation for mobile testing; the compact Getein 1100 delivers high-precision testing with both in-device and external testing modes for flexible deployment; and CM-50 Vet combines a disc-shaped reagent cartridge with dry chemistry technology to enable convenient multi-analyte testing in veterinary setting. These featured instruments represent part of Getein's broader portfolio of diagnostic platforms and solutions developed for diverse testing needs.     Still On - Don't Miss Out India Health 2026 continues through August 23. Visit Getein at Hall 6, Booth C12 to discover our latest diagnostic solutions and discuss new opportunities for collaboration.    

Connecting Partners, Empowering Growth | Getein Hosts India Distributor Meeting Strengthening Partnerships in India     Getein Biotech, together with its local partner Ares Labs, hosted the 2026 India Distributor Meeting on August 20 2026, at SK Premium Park in New Delhi. Held under the theme "Grow Together, Win the Future," the meeting brought together representatives from leading diagnostic companies across India. Partners and industry professionals exchanged insights, explored opportunities for collaboration, and discussed the future of India's diagnostics market. The event provided an open platform for closer cooperation. It also highlighted Getein's commitment to bringing reliable, high-performance in vitro diagnostic (IVD) solutions to Indian healthcare institutions while supporting the development of local laboratory capabilities. Guests arrived in the afternoon and took part in informal conversations before the meeting began. The event officially opened at 5:00 p.m. with remarks from Getein's overseas sales team, who thanked all partners for their continued trust and support.     Technology Showcase     During the main session, the Getein team introduced the company's expertise and latest developments across three product lines: chemiluminescence, point-of-care testing (POCT), and hematology.     The fully automated MAGICL 6000 and MAGICL 6000i chemiluminescence immunoassay analyzers are designed to meet laboratories' different throughput requirements, offering a balance of efficiency, accuracy, and reliability. Getein's POCT portfolio ranges from portable semi-automated devices to fully automated, high-throughput systems. These solutions support a variety of settings, including emergency care, decentralized testing, and central laboratories. The BHA series of hematology analyzers includes both 3-part and 5-part differential models, providing complete blood count solutions for a broad range of clinical applications.The BHA series of hematology analyzers includes both 3-part and 5-part differential models, providing complete blood count solutions for a broad range of clinical applications. Participants showed strong interest in the products' technical performance and clinical value. Discussions covered reagent stability, assay menus, equipment capabilities, and laboratory implementation, creating an engaging and productive atmosphere. Clinical Insights The open discussion session focused on practical needs in the Indian market. Participants shared their experience with hospital laboratories and clinical workflows and raised questions about equipment maintenance, testing efficiency, and local service support. These exchanges offered valuable insights into local operating conditions and provided a basis for further cooperation between Getein and its Indian partners.     Growing Together India is one of the world's most dynamic diagnostics markets, with significant potential for continued grow...